Phase I study of ERY-ASP in newly diagnosed Acute-lymphoblastic-leukaemia (ALL)

Trial Profile

Phase I study of ERY-ASP in newly diagnosed Acute-lymphoblastic-leukaemia (ALL)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 11 Sep 2017

At a glance

  • Drugs ERY-ASP (Primary)
  • Indications Acute lymphoblastic leukaemia
  • Focus Therapeutic Use
  • Most Recent Events

    • 11 Sep 2017 According to an ERYtech Pharma media release, all patients in the third dose escalation cohort of this study have been treated and a decision on the recommended phase 2 dosing is expected in the coming weeks, which will enable the company to begin planning of a pivotal phase 3 study.
    • 02 Mar 2017 According to an ERYTECH media release, this trial is expected to reach the recommended phase 2 dose in mid-2017.
    • 03 Nov 2016 According to an ERYTECH media release, enrollment in the second cohort has been completed and recommended phase II dose is expected in the first quarter of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top